204 related articles for article (PubMed ID: 28854927)
21. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
Fontrier AM
Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
[TBL] [Abstract][Full Text] [Related]
22. Using 5 consecutive years of NICE guidance to describe the characteristics and influencing factors on the economic evaluation of orphan oncology drugs.
Shengnan D; Zixuan L; Na Z; Weikai Z; Yuanyuan Y; Jiasu L; Ni Y
Front Public Health; 2022; 10():964040. PubMed ID: 36187695
[TBL] [Abstract][Full Text] [Related]
23. Evidence and values: paying for end-of-life drugs in the British NHS.
Chalkidou K
Health Econ Policy Law; 2012 Oct; 7(4):393-409. PubMed ID: 23079299
[TBL] [Abstract][Full Text] [Related]
24. Health economic evaluation in England.
Raftery J
Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):367-74. PubMed ID: 25444294
[TBL] [Abstract][Full Text] [Related]
25. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
[TBL] [Abstract][Full Text] [Related]
26. New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.
Varnava A; Bracchi R; Samuels K; Hughes DA; Routledge PA
Pharmacoeconomics; 2018 May; 36(5):613-624. PubMed ID: 29520603
[TBL] [Abstract][Full Text] [Related]
27. DECISION-COMPONENTS OF NICE'S TECHNOLOGY APPRAISALS ASSESSMENT FRAMEWORK.
de Folter J; Trusheim M; Jonsson P; Garner S
Int J Technol Assess Health Care; 2018 Jan; 34(2):163-171. PubMed ID: 29633673
[TBL] [Abstract][Full Text] [Related]
28. Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey.
Polisena J; Burgess M; Mitton C; Lynd LD
BMC Health Serv Res; 2017 May; 17(1):372. PubMed ID: 28549479
[TBL] [Abstract][Full Text] [Related]
29. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
30. Public funding of new cancer drugs: Is NICE getting nastier?
Mason AR; Drummond MF
Eur J Cancer; 2009 May; 45(7):1188-1192. PubMed ID: 19138512
[TBL] [Abstract][Full Text] [Related]
31. Drugs for exceptionally rare diseases: do they deserve special status for funding?
Hughes DA; Tunnage B; Yeo ST
QJM; 2005 Nov; 98(11):829-36. PubMed ID: 16203824
[TBL] [Abstract][Full Text] [Related]
32. Impact of a novel prioritization framework on clinician-led oncology drug submissions.
Keech J; Beca J; Eisen A; Kennedy E; Kim J; Kouroukis CT; Darling G; Ferguson SE; Finelli A; Petrella TM; Perry JR; Chan K; Gavura S
Curr Oncol; 2019 Apr; 26(2):e155-e161. PubMed ID: 31043821
[TBL] [Abstract][Full Text] [Related]
33. NICE guidance in the Scottish context.
Kohli H; Tannahill A
Scott Med J; 2009 Feb; 54(1):35-8. PubMed ID: 19291935
[TBL] [Abstract][Full Text] [Related]
34. Budget impact of rare diseases: proposal for a theoretical framework based on evidence from Bulgaria.
Iskrov G; Jessop E; Miteva-Katrandzhieva T; Stefanov R
Georgian Med News; 2015 May; (242):46-53. PubMed ID: 26042447
[TBL] [Abstract][Full Text] [Related]
35. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
[TBL] [Abstract][Full Text] [Related]
36. Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain.
Linley WG; Hughes DA
Health Econ; 2013 Aug; 22(8):948-64. PubMed ID: 22961976
[TBL] [Abstract][Full Text] [Related]
37. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
Wong CKH; Wu O; Cheung BMY
Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
[TBL] [Abstract][Full Text] [Related]
38. Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries.
Efthymiadou O; Kanavos P
Int J Technol Assess Health Care; 2021 Jan; 37():e31. PubMed ID: 33509311
[TBL] [Abstract][Full Text] [Related]
39. Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs.
Costa S; Bentley C; Regier DA; McTaggart-Cowan H; Mitton C; Burgess MM; Peacock SJ
BMC Public Health; 2019 Jul; 19(1):977. PubMed ID: 31331312
[TBL] [Abstract][Full Text] [Related]
40. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
